vantictumab

DRUG2 trials

Sponsors

OncoMed Pharmaceuticals, Inc.

Conditions

Pancreatic CancerSolid TumorsStage IV Pancreatic Cancer

Phase 1

A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

CompletedNCT01957007

OncoMed Pharmaceuticals, Inc.Solid Tumors

Start: 2013-09-30End: 2017-06-30Target: 34Updated: 2020-09-09

A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

CompletedNCT02005315

OncoMed Pharmaceuticals, Inc.Pancreatic Cancer, Stage IV Pancreatic Cancer

Start: 2013-09-30End: 2017-11-30Updated: 2020-09-09

Related Papers

A phase Ib dose escalation study of vantictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer.

Journal of Clinical Oncology2019-01-295 citations

Abstract 3129: Predictive biomarker identification for response to vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts

Cancer Research2016-07-153 citations

Abstract A30: Predictive and pharmacodynamic biomarkers of vantictumab (OMP-18R5; anti-Frizzled) in non-small cell lung cancer

Molecular Cancer Therapeutics2015-12-012 citations